Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia
In order to determine the effects of pravastatin (Pra) on angiogenic and placental hypoxic imbalance in a model of preeclampsia induced by overexpression of soluble fms-like tyrosine kinase 1 (sFlt-1), we randomly allocated pregnant CD1 mice to injection with adenovirus-carrying sFlt-1 or mFc (control). The sFlt-1 group received either Pra (sFlt-1 + Pra) or water (sFlt-1). Mice were sacrificed at day 18, and serum levels of sFlt-1 and soluble endoglin (sEng) were measured. Placental expression of placental (PLGF) and vascular endothelial (VEGF) growth factors and other markers of angiogenesis and hypoxia were assayed. We observed that Pra treatment in sFlt-1 mice reduced sFlt-1 and sEng concentrations at day 18 to levels similar to control group. Placental PLGF and VEGF expression were upregulated, and markers of hypoxia downregulated to levels similar to control group. Hence, Pra prevents the rise in circulating antiangiogenic factors in a mouse model of preeclampsia. Statins may represent a novel approach to prevention of preeclampsia.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Reproductive sciences (Thousand Oaks, Calif.) - 21(2014), 1 vom: 25. Jan., Seite 138-45 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Saad, Antonio F [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 17.06.2014 Date Revised 25.11.2016 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/1933719113492207 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM228191785 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM228191785 | ||
| 003 | DE-627 | ||
| 005 | 20231224075344.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/1933719113492207 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0760.xml |
| 035 | |a (DE-627)NLM228191785 | ||
| 035 | |a (NLM)23749761 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Saad, Antonio F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.06.2014 | ||
| 500 | |a Date Revised 25.11.2016 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In order to determine the effects of pravastatin (Pra) on angiogenic and placental hypoxic imbalance in a model of preeclampsia induced by overexpression of soluble fms-like tyrosine kinase 1 (sFlt-1), we randomly allocated pregnant CD1 mice to injection with adenovirus-carrying sFlt-1 or mFc (control). The sFlt-1 group received either Pra (sFlt-1 + Pra) or water (sFlt-1). Mice were sacrificed at day 18, and serum levels of sFlt-1 and soluble endoglin (sEng) were measured. Placental expression of placental (PLGF) and vascular endothelial (VEGF) growth factors and other markers of angiogenesis and hypoxia were assayed. We observed that Pra treatment in sFlt-1 mice reduced sFlt-1 and sEng concentrations at day 18 to levels similar to control group. Placental PLGF and VEGF expression were upregulated, and markers of hypoxia downregulated to levels similar to control group. Hence, Pra prevents the rise in circulating antiangiogenic factors in a mouse model of preeclampsia. Statins may represent a novel approach to prevention of preeclampsia | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a angiogenesis | |
| 650 | 4 | |a placental growth factor | |
| 650 | 4 | |a pravastatin | |
| 650 | 4 | |a preeclampsia | |
| 650 | 4 | |a soluble endoglin | |
| 650 | 7 | |a Endoglin |2 NLM | |
| 650 | 7 | |a Eng protein, mouse |2 NLM | |
| 650 | 7 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors |2 NLM | |
| 650 | 7 | |a Intracellular Signaling Peptides and Proteins |2 NLM | |
| 650 | 7 | |a Pgf protein, mouse |2 NLM | |
| 650 | 7 | |a Pregnancy Proteins |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a Vascular Endothelial Growth Factor A |2 NLM | |
| 650 | 7 | |a vascular endothelial growth factor A, mouse |2 NLM | |
| 650 | 7 | |a Placenta Growth Factor |2 NLM | |
| 650 | 7 | |a 144589-93-5 |2 NLM | |
| 650 | 7 | |a Vascular Endothelial Growth Factor Receptor-1 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Pravastatin |2 NLM | |
| 650 | 7 | |a KXO2KT9N0G |2 NLM | |
| 700 | 1 | |a Kechichian, Talar |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Huaizhi |e verfasserin |4 aut | |
| 700 | 1 | |a Sbrana, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Longo, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Wen, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Tamayo, Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Hankins, Gary D V |e verfasserin |4 aut | |
| 700 | 1 | |a Saade, George R |e verfasserin |4 aut | |
| 700 | 1 | |a Costantine, Maged M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Reproductive sciences (Thousand Oaks, Calif.) |d 2007 |g 21(2014), 1 vom: 25. Jan., Seite 138-45 |w (DE-627)NLM171524403 |x 1933-7205 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2014 |g number:1 |g day:25 |g month:01 |g pages:138-45 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/1933719113492207 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2014 |e 1 |b 25 |c 01 |h 138-45 | ||